$0.58
3.92%
Nasdaq, Oct 20, 01:48 pm EDT. Market open.
ISIN
US0050831009
Symbol
ACTU

Actuate Therapeutics Stock price

$0.60
-0.31 33.96% 1M
-2.02 77.14% 6M
-5.52 90.21% YTD
-6.79 91.89% 1Y
-7.40 92.51% 3Y
-7.40 92.51% 5Y
-7.40 92.51% 10Y
-7.40 92.51% 20Y
Nasdaq, Closing price Mon, Oct 19 2026
-0.01 0.99%
ISIN
US0050831009
Symbol
ACTU
Industry

Is Actuate Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,109 stocks worldwide.

Key metrics

Basic
Market capitalization
$14.4m
Enterprise Value
$10.4m
Net debt
positive
Cash
$4.4m
Shares outstanding
24.0m
Valuation
P/E
negative
P/S | estimate
- | -
EV/Sales | estimate
- | -
EV/FCF | ex SBC
negative | negative
P/B
14.5
Financial Health
Equity Ratio
56.5%
Return on Equity
-280.5%
ROCE
-1,494.5%
ROIC
-
Debt/Equity
0.4
Share-Based Compensation & Dilution
SBC | % of Revenue
$6.0m | -
SBC as % of FCF
-
SBC Growth 1Y
35.4%
Share Count Growth 1Y
17.3%
Shareholder Yield
-17.3%
Financials
Revenue | estimate
$0.0 | $0.0
EBITDA
-
EBIT
$-20.8m
Net Income
$-20.5m
Free Cash Flow | ex SBC
$-19.8m | $-25.9m
Growth
Revenue | estimate
- | -
EBITDA
-
EBIT
13.2%
Net Income
17.1%
Free Cash Flow
12.6%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow | ex SBC
- | -
More
EPS
$-0.9
FCF per Share
$-0.8
Short interest
12.6%
Employees
12
Rev per Employee
$0.0

Actuate Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Actuate Therapeutics forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Actuate Therapeutics forecast:

Buy
89%
Hold
11%

Financial data from Actuate Therapeutics

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 12 12
9% 9%
-
- Research and Development Expense 8.94 8.94
33% 33%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -21 -21
13% 13%
-
Net Profit -20 -20
17% 17%
-

In millions USD.

Don't miss a Thing! We will send you all news about Actuate Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Actuate Therapeutics Stock News

Neutral
GlobeNewsWire
●
about one month ago
CHICAGO and FORT WORTH, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing novel therapies for high-impact, difficult-to-treat cancers, today announced new preclinical data evaluating elraglusib in combination with zoldonrasib (RMC-9805), an investigational RAS(ON) G1...
Neutral
GlobeNewsWire
●
4 months ago
- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham  - Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma - Complete response in neuroblastoma patient achieved in Phase 1 study...
Neutral
GlobeNewsWire
●
5 months ago
- Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall survival (mOS) when treated with elraglusib plus gemcitabine/Abraxane (GnP) versus GnP alone - Patients with P53WT genomics receiving elraglusib plus GnP showed a near doubling of mOS versus GnP alone - Patients receiving elraglusib plus FOLFIRINOX demonstrated deep and sustained clinical responses a...
More Actuate Therapeutics News

Company Profile

Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX.

Head office United States
CEO Mr. Schmitt
Employees 12
Website actuatetherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today